2025 United Kingdom Antisense And Rnai Therapeutics Market Revenue Opportunities Report
Description
The 2025 United Kingdom Antisense And Rnai Therapeutics Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antisense and RNAi Therapeutics market in the United Kingdom are GlaxoSmithKline (GSK) plc, Silence Therapeutics PLC, Sarepta Therapeutics Inc, and Alnylam Pharmaceuticals Inc. GSK, headquartered in Brentford, UK, is a major pharmaceutical company with over 70,000 employees and significant involvement in antisense and RNAi drug development. Silence Therapeutics, based in London, specializes in RNAi therapeutics and focuses on leveraging RNA interference technologies for gene regulation. Sarepta Therapeutics and Alnylam Pharmaceuticals, although headquartered in the US, have strong research and commercial presence influencing the UK market through innovation in RNA-based therapies targeting genetic diseases.
These companies drive the UK's market growth by developing advanced gene-silencing drugs using antisense oligonucleotides and siRNA technologies, which selectively inhibit disease-causing gene expression. The UK antisense and RNAi market benefits from government investments and increasing demand for treatments for genetic and neurodegenerative diseases. Strategic collaborations, such as those pursued by these companies, accelerate drug discovery and regulatory approval processes, enhancing therapeutic options. GSK and Silence Therapeutics particularly focus on expanding RNAi pipelines domestically, while Sarepta and Alnylam contribute through global innovations integrated into the UK biotechnology ecosystem.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antisense and RNAi Therapeutics market in the United Kingdom are GlaxoSmithKline (GSK) plc, Silence Therapeutics PLC, Sarepta Therapeutics Inc, and Alnylam Pharmaceuticals Inc. GSK, headquartered in Brentford, UK, is a major pharmaceutical company with over 70,000 employees and significant involvement in antisense and RNAi drug development. Silence Therapeutics, based in London, specializes in RNAi therapeutics and focuses on leveraging RNA interference technologies for gene regulation. Sarepta Therapeutics and Alnylam Pharmaceuticals, although headquartered in the US, have strong research and commercial presence influencing the UK market through innovation in RNA-based therapies targeting genetic diseases.
These companies drive the UK's market growth by developing advanced gene-silencing drugs using antisense oligonucleotides and siRNA technologies, which selectively inhibit disease-causing gene expression. The UK antisense and RNAi market benefits from government investments and increasing demand for treatments for genetic and neurodegenerative diseases. Strategic collaborations, such as those pursued by these companies, accelerate drug discovery and regulatory approval processes, enhancing therapeutic options. GSK and Silence Therapeutics particularly focus on expanding RNAi pipelines domestically, while Sarepta and Alnylam contribute through global innovations integrated into the UK biotechnology ecosystem.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
